Notice for caplacizumab (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
caplacizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection, intravenous
Indication
For the treatment of Thrombotic Thrombocytopenic Purpura (TTP)
Therapeutic area
Haematology